UNSPSC 51295303: Trazium esilate

This classification denotes an antidepressant agent with the molecular formula C17H13ClN3O.C2H5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PO9LWW5IN, chemically known as 1-(p-chlorophenyl)-1,2-dihydro-1-hydroxy-as-triazino(6,1-a)isoquinolin-5-ium ethanesulfonate but generally known as trazium esilate, which bears US NIH Compound Identifier 72166. European Medicines Agency schedules Trazium esilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11223MIG.

UNSPSC 51295303 Trazium esilate (Commodity) covers pharmaceutical products and related drug-distribution systems being procured by state and local health agencies, though the recent solicitations tagged under this code diverge significantly from trazium esilate specifically—they describe naloxone, generic multi-source pharmaceuticals, OTC products, and direct-to-manufacturer prescription fulfillment. The code appears to function as a catch-all for state and local pharmaceutical and drug-delivery procurement rather than a precise product match. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing consortia that serve multi-state networks of state and local government facilities. The Seminole County, Florida procurement sought naloxone and drug deactivation systems for community health delivery; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic pharmaceuticals and OTC products through a formal RFP with authorized-wholesaler distribution; and the Texas Health and Human Services Commission issued an RFI to gather vendor intelligence on direct-to-manufacturer prescription programs. These represent a mix of transactional procurements (county IFB, cooperative RFP) and exploratory market research (state RFI).

Recent activity concentrates in Texas, Minnesota (serving multi-state participation including Oregon), and Florida, with the competitive landscape shaped by cooperative-purchasing frameworks, mandatory wholesaler relationships, and compliance with federal pharmaceutical regulations including cGMP and DSCSA requirements. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought annual delivery of 1,900 units of naloxone and 800 drug deactivation systems through quarterly shipments to a community health building. The Minnesota MMCAP RFP (Solicitation S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products, effective July 1, 2026, with evaluation weighted heavily toward price competitiveness (75 percent), cGMP and DSCSA compliance, and mandatory relationships with at least two of three authorized wholesalers. The Texas HHS RFI (HHS0017013, response deadline April 3, 2026) gathered vendor capabilities for direct manufacturer contracting outside traditional PBM and GPO channels. All three solicitations require vendor drug-free workplace certification, federal regulatory compliance, and insurance coverage; neither the Seminole nor MMCAP procurements explicitly designated set-asides for disadvantaged enterprises.